CARDIOGENESIS' TRANSMYOCARDIAL REVASCULARIZATION SYSTEM PHASE I STUDY BEGINS; COMPANY EMPHASIZING LOW COST, PERCUTANEOUS CAPACITY OF HOLMIUM LASER
This article was originally published in The Gray Sheet
Executive Summary
CardioGenesis' transmyocardial revascularization Phase I clinical trial is "under way," company President and CEO Allen Hill said at the Piper Jaffray Medical Device Conference Feb. 6. One patient has been treated in the study, which will involve a total of 12 patients. Three U.S. and six European sites are expected to participate in the trial.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.